Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LINZESS vs AKBETA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Linaclotide is a guanylate cyclase-C (GC-C) agonist that activates GC-C on the luminal surface of intestinal epithelial cells, increasing intracellular cyclic guanosine monophosphate (c GMP) levels. Elevated c GMP stimulates chloride and bicarbonate secretion into the intestinal lumen, increasing fluid secretion and accelerating gastrointestinal transit. Additionally, it reduces visceral pain by decreasing activity of pain-sensing nerves.
AKBETA is not a recognized drug; please verify the drug name.
Treatment of irritable bowel syndrome with constipation (IBS-C) in adults,Treatment of chronic idiopathic constipation (CIC) in adults,Off-label: Treatment of constipation-predominant IBS in pediatric patients (limited data)
No verified indications
72 mcg to 290 mcg orally once daily on an empty stomach at least 30 minutes before the first meal of the day.
Metoprolol tartrate: 50-100 mg orally twice daily; metoprolol succinate: 25-200 mg orally once daily.
Terminal half-life is 6.6 hours (range 4 – 12 h) in healthy subjects; not prolonged in renal or hepatic impairment.
Terminal elimination half-life is 3-5 hours in patients with normal renal function; prolonged to 10-20 hours in severe renal impairment.
Linaclotide is minimally absorbed systemically and is metabolized within the gastrointestinal tract to its active peptide. No significant hepatic metabolism occurs; the primary route of elimination is fecal excretion as the active peptide.
Unknown
Primarily fecal (95%) as intact drug; renal excretion accounts for <1%.
Renal excretion accounts for 80-85% of the dose, primarily as unchanged drug; biliary/fecal elimination is 10-15%.
Approximately 94% bound to human serum albumin.
60-70% bound primarily to albumin and alpha-1-acid glycoprotein.
Mean Vd is 4.4 L/kg, indicating extensive extravascular distribution into tissues.
Vd is 1.0-2.0 L/kg, indicating extensive tissue distribution.
Oral bioavailability is approximately 4% due to extensive first-pass metabolism and low systemic absorption.
Oral: 50-60% due to first-pass hepatic metabolism; IV: 100%.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment or end-stage renal disease; use cautiously.
No dose adjustment required for mild to moderate renal impairment; in severe renal impairment (GFR < 10 m L/min), administer with caution.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended in severe hepatic impairment (Child-Pugh C) due to lack of data.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
For functional constipation in pediatric patients: 72 mcg orally once daily for ages 6-17 years. Safety and efficacy not established below 6 years.
1-2 mg/kg per day orally in divided doses; maximum 200 mg/day.
No specific dose adjustment; start at 72 mcg daily. Monitor for diarrhea and electrolyte disturbances, especially in patients >65 years.
Initiate at lower end of dosing range (e.g., 25 mg once daily for metoprolol succinate), titrate slowly due to increased risk of bradycardia and hypotension.
WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE. Linaclose is contraindicated in pediatric patients up to 6 years of age. In young juvenile mice, linaclotide caused deaths due to dehydration; this risk was highest in mice less than 3 weeks of age (approximately equivalent to human pediatric patients less than 2 years of age). Use LINZESS in pediatric patients from 6 to less than 18 years of age only for the treatment of functional constipation (FC) and after evaluating the risk of dehydration and ensuring adequate fluid intake.
No boxed warning applicable
Risk of serious dehydration in pediatric patients less than 2 years of age; contraindicated in patients up to 6 years of age.,Diarrhea: May cause severe diarrhea, especially during the first few weeks of treatment; if severe, discontinue use and rehydrate.,Do not use in patients with known or suspected mechanical gastrointestinal obstruction.
No warnings due to lack of data
Pediatric patients up to 6 years of age (risk of serious dehydration).,Known or suspected mechanical gastrointestinal obstruction.,Hypersensitivity to linaclotide or any component of the formulation.
No contraindications identified
Take on an empty stomach; avoid taking with food as food reduces absorption and efficacy.
No significant food interactions. Taking with meals may reduce gastrointestinal irritation. Avoid excessive salt intake as it may exacerbate Meniere's symptoms.
Linzess (linaclotide) is a guanylate cyclase-C agonist. Animal studies (rats, rabbits) at doses up to 800 mcg/kg/day showed no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. Based on animal data, the risk of major birth defects is low, but due to lack of human data, use only if clearly needed. First trimester: No known specific risk. Second and third trimesters: No known specific risk. No placental transfer data available; linaclotide is a large peptide with minimal systemic absorption, likely negligible fetal exposure.
Pregnancy category D. First trimester: Associated with fetal bradycardia, hypoglycemia, and growth restriction; beta-blocker exposure increases risk of low birth weight. Second trimester: Continued risk of fetal bradycardia and growth restriction; may cause placental hypoperfusion. Third trimester: Risk of neonatal hypoglycemia, bradycardia, and respiratory depression; beta-blockade may attenuate fetal heart rate response to distress.
No human data on linaclotide excretion in breast milk. Animal studies show low levels in rat milk with M/P ratio approximately 0.1-0.2. Due to minimal systemic absorption after oral administration, excretion into human milk is expected to be negligible. However, caution is advised. No adverse effects observed in nursing pups in animal studies. Consider benefits vs risks.
Atenolol is excreted in breast milk with a high M/P ratio of approximately 4.6. Peak milk levels occur 2-4 hours after dose. Due to potential for infant bradycardia and hypoglycemia, use is not recommended; if used, monitor infant for signs of beta-blockade.
No pharmacokinetic data on linaclotide in pregnancy. Due to minimal systemic absorption, significant pharmacokinetic changes are unlikely. No dose adjustment recommended in pregnancy. Standard dosing for chronic idiopathic constipation or irritable bowel syndrome with constipation (145 mcg or 290 mcg once daily) may be used if clinically indicated. Use caution in third trimester if risk of dehydration due to diarrhea.
Atenolol is not recommended in pregnancy due to fetotoxicity; use alternative beta-blocker with better safety profile (e.g., labetalol). If used, dose requirements may increase due to expanded plasma volume and increased renal clearance; dose should be individualized based on maternal heart rate and blood pressure response.
Initiate at 290 mcg daily for IBS-C; 145 mcg daily for CIC; take on empty stomach at least 30 minutes before first meal; capsules must be swallowed whole; clinical response may take 2-4 weeks; contraindicated in patients with known or suspected mechanical GI obstruction; avoid in pediatric patients less than 2 years of age due to risk of serious diarrhea and dehydration.
AKBETA (betahistine) is primarily used for Meniere's disease. Titrate dose gradually to minimize GI upset. Avoid in patients with pheochromocytoma or severe asthma. Monitor for hypotension and bradycardia. Efficacy may take weeks to manifest.
Take LINZESS at least 30 minutes before your first meal of the day on an empty stomach.,Swallow capsules whole; do not crush, chew, or open them.,Do not take LINZESS if you have a bowel blockage (intestinal obstruction).,Common side effects include diarrhea, abdominal pain, and gas; severe diarrhea may occur, especially in children under 2 years.,Tell your doctor if you have severe or persistent diarrhea, or if you experience symptoms of dehydration.
Take with or after meals to reduce stomach upset.,Do not drive or operate machinery if you experience dizziness or drowsiness.,Report any worsening of asthma symptoms or irregular heartbeat.,Avoid alcohol as it may increase side effects like dizziness.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LINZESS vs AKBETA, answered by our medical review team.
LINZESS is a Guanylate Cyclase-C Agonist that works by Linaclotide is a guanylate cyclase-C (GC-C) agonist that activates GC-C on the luminal surface of intestinal epithelial cells, increasing intracellular cyclic guanosine monophosphate (c GMP) levels. Elevated c GMP stimulates chloride and bicarbonate secretion into the intestinal lumen, increasing fluid secretion and accelerating gastrointestinal transit. Additionally, it reduces visceral pain by decreasing activity of pain-sensing nerves.. AKBETA is a Beta Blocker (Ophthalmic) that works by AKBETA is not a recognized drug; please verify the drug name.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LINZESS and AKBETA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LINZESS is: 72 mcg to 290 mcg orally once daily on an empty stomach at least 30 minutes before the first meal of the day.. The standard adult dose of AKBETA is: Metoprolol tartrate: 50-100 mg orally twice daily; metoprolol succinate: 25-200 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LINZESS and AKBETA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LINZESS is classified as Category C. Linzess (linaclotide) is a guanylate cyclase-C agonist. Animal studies (rats, rabbits) at doses up to 800 mcg/kg/day showed no evidence of teratogenicity. There are no adequate and. AKBETA is classified as Category C. Pregnancy category D. First trimester: Associated with fetal bradycardia, hypoglycemia, and growth restriction; beta-blocker exposure increases risk of low birth weight. Second tri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.